A photo of David Neal Franz.

Founding Director, Tuberous Sclerosis Clinic

Associate Director of Clinical Affairs, Division of Neurology

Professor, UC Department of Pediatrics



Board Certified

Best Doctors logo

"I believe in providing the best care and treatment for my patients and families, whatever that may be."

My Biography & Research


As a brain doctor, I care for children with general neurologic conditions. I specialize in neurocutaneous disorders and neuropharmacology. I’m the founding director of the Tuberous Sclerosis Clinic at Children’s Hospital Medical Center.

I believe in providing the best care and treatment for my patients and families, whatever that may be.

At Cincinnati Children’s we try our sincere best to help patients and families living with a complex neurological and medical diagnosis. Many of these conditions do not have established or approved therapies.

My research focuses on targeted therapies for epilepsy and genetic brain disorders.

Additional Languages


Clinical Interests

Tuberous sclerosis (adults and children); neuropharmacology; neurocutaneous disorders; general pediatric neurology

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Neurology, Tuberous Sclerosis, Sturge-Weber Syndrome

Research Divisions


My Locations

  • Mason


    9560 Children's Drive
    Mason, Ohio 45040

My Education

MD: Ohio State University College of Medicine, Columbus, OH, 1985.

Residency: Wright State University Affiliated Hospitals, Dayton, OH.

Fellowship: Children's Hospital Medical Center, Cincinnati, OH.

Certification: Pediatrics, 1990, 2016; Neurology with special competence in child neurology, 1992.

My Publications

Lymphangioleiomyomatosis Association with Underlying Genotype in Patients with Tuberous Sclerosis Complex. Tian, X; Glass, JE; Kwiatkowski, DJ; Towbin, AJ; Li, Y; Sund, KL; Krueger, DA; Franz, DN; McCormack, FX; Gupta, N. Annals of the American Thoracic Society. 2021; 18:815-819.

Frequency, Progression, and Current Management: Report of 16 New Cases of Nonfunctional Pancreatic Neuroendocrine Tumors in Tuberous Sclerosis Complex and Comparison With Previous Reports. Mowrey, K; Northrup, H; Rougeau, P; Hashmi, SS; Krueger, DA; Ebrahimi-Fakhari, D; Towbin, AJ; Trout, AT; Capal, JK; Franz, DN; et al. Frontiers in Neurology. 2021; 12.

mTOR Inhibitor Therapy for Tuberous Sclerosis Complex: Longitudinal Study of Muscle Mass Determined by Abdominal Cross-sectional Imaging with CT and MRI. Raab, C; Gilligan, LA; Trout, AT; Krueger, DA; Franz, DN; Zhang, B; Towbin, AJ. Radiology. Imaging cancer. 2020; 2.

Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA). Ebrahimi-Fakhari, D; Franz, DN. Expert Opinion on Pharmacotherapy. 2020; 21:1329-1336.

Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex. Ebrahimi-Fakhari, D; Agricola, KD; Tudor, C; Krueger, D; Franz, DN. Pediatric Neurology. 2020; 105:59-61.

Congenital Lymphatic Malformation and Aortic Aneurysm in a Patient with TSC2 Mutation. Wiemer-Kruel, A; Mayer, H; Ewert, P; Martinoff, S; Eckstein, H; Kriebel, T; Bissler, J; Franz, D; Bast, T. Neuropediatrics. 2020; 51:57-61.

Clinical Letter: A case report of targeted therapy with sirolimus for NPRL3 epilepsy. Vawter-Lee, M; Franz, DN; Fuller, CE; Greiner, HM. Seizure : the journal of the British Epilepsy Association. 2019; 73:43-45.

Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures. Lechuga, L; Franz, DN. Expert Review of Neurotherapeutics. 2019; 19:913-925.

Everolimus for cognition/autism in children with tuberous sclerosis complex: Definitive outcomes deferred. Ess, KC; Franz, DN. Neurology. 2019; 93:51-52.

Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2. Bissler, JJ; Budde, K; Sauter, M; Franz, DN; Zonnenberg, BA; Frost, MD; Belousova, E; Berkowitz, N; Ridolfi, A; Kingswood, JC. Nephrology Dialysis Transplantation. 2019; 34:1000-1008.